Global Markets for Research Antibodies

Report Highlights

The global market for research antibodies is estimated to increase from $3.7 billion in 2023 to reach $5.8 billion by 2028, at a compound annual growth rate (CAGR) of 9.2% from 2023 through 2028.

Report Includes

• 145 data tables and 45 additional tables
• An overview of the global market landscape related to the research antibodies
• In-depth analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, as well as forecasts for 2028. This analysis includes projections of Compound Annual Growth Rates (CAGRs) spanning through 2028
• Evaluation of the current market size and revenue growth prospects specific to research antibodies, accompanied by a comprehensive market share analysis categorized by product, clonality, application, major reactivities, host species, end-user, and geographical region
• Discussion on the factors affecting the companies’ market shares, the current strategies of antibody companies, the effect of research funding, and the third-party quality evaluation systems of research antibodies
• Description of antibody technologies, emerging antibody generation technologies and identification of market drivers, restraints and other forces impacting the global market
• Discussion on technological trends in antibody production and application, and information on antibody-based drug discovery and development process
• Impact analysis of COVID-19 on entire pharma industry and discussion on how COVID-19 is related to pharmaceutical industry’s growth slow-down and results in delayed approvals for non-COVID-19-related pharmaceutical/biotech products
• Coverage of new discoveries in biological sciences, rapid technological developments in the IVD industry, new antibody technologies and antibody types, and assessment of antibody-based drug discovery and development
• Discussion on advantages and disadvantages of antibody discovery technologies with examples of antibody production, and information on REpAb technology
• Coverage of FDA and international regulations, details of recent regulatory reforms and list of antibody therapeutics granted in 2018 and insights into government initiatives and funding in emerging markets
• Examination of environmental, social, and corporate governance (ESG) developments, a relevant patent analysis; and merger and acquisitions (M&A), venture fundings, and emerging technologies in the global research antibodies
• Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses, including Abcam Plc, Thermo Fisher Scientific Inc., Cell Signaling Technology Inc., Merck KGaA, Sino Biological Inc., and Bio-Rad

Report Scope

This study focuses on the market side of research antibodies, as opposed to the technical side. Different market segments for this specific market are covered. Application-based market segments include enzyme-linked immunosorbent assay (ELISA), western blotting (WB), immunohistochemistry (IHC)(types of tissue multiplexing segments), immunofluorescent staining (IF), immunoprecipitation and flow cytometry (FC); antibody function-based market segments include primary antibodies and secondary antibodies; antibody clonality-based market segments include polyclonal antibodies and monoclonal antibodies, including recombinant antibodies; customer type-based market segments include universities and academic institutions, pharmaceutical and biotech companies and other types of customers (e.g., governmental research labs, contract research organizations [CROs]); geography-based market segments include North America, Europe, Asia-Pacific and Rest of World. Research and market trends are also extrapolated by analyzing the funding, patent publications and sales trends of major players in the field.

In this report, the market for research antibodies is segmented based on product type, clonality, host species, major reactivities, applications, end-user, and geography. Based on application type, the market is segmented into enzyme-linked immunosorbent assay (ELISA), western blotting (WB), immunohistochemistry (IHC) (i.e., types of tissue multiplexing segments), immunofluorescent staining (IF), immunoprecipitation and flow cytometry (FC). Based on major reactivities, the market is segmented into anti-human, anti-rat and anti-mouse. The market is also presented based on product type, which is further segmented into primary and secondary antibodies.

The market has been geographically segmented into the North America, Europe, Asia-Pacific and Rest of the World (i.e., South America, Middle East and Africa) regions. Detailed analysis of major countries (e.g., the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, and GCC countries) will be covered in the regional segment. For market estimates, data will be provided for 2022 as the base year, with estimates for 2023 and forecast value for 2028.

Analyst Credentials

Partha Sarathi Das– Associate Consultant-Life Science Research
Partha Sarathi has an experience of nearly a decade in multiple domains, including healthcare, life science, biotechnology, pharmaceuticals, and healthcare IT. His expertise is in designing research studies, gathering data, and performing analysis, ultimately providing clients with actionable insights and recommendations based on their unique business needs. Designs proposal and participates in client queries for quick delivery based on their unique business needs. Academically, Parthasarathi holds a master’s degree in Biotechnology and a bachelor’s degree in Industrial Biotechnology.

Consulting Editor’s Credentials

Dr. Marianna Tcherpakov has more than 10 years of experience as a bench scientist specializing in the areas of biochemistry, cell biology, assay development, antibody and drug manufacturing. She has authored several scientific publications in peer review journals. In the last 10 years, Marianna worked as a business development professional in CRO/CDMO industry. She is familiar with pharmaceutical and biotech landscape, trends and potential future developments in industry.